Factory Supply Rece...

Factory Supply Recentin/Cediranib CAS NO.288383-20-0
Factory Supply Recentin/Cediranib CAS NO.288383-20-0
Factory Supply Recentin/Cediranib CAS NO.288383-20-0
Factory Supply Recentin/Cediranib CAS NO.288383-20-0
Factory Supply Recentin/Cediranib CAS NO.288383-20-0
Factory Supply Recentin/Cediranib CAS NO.288383-20-0

Factory Supply Recentin/Cediranib CAS NO.288383-20-0

Min.Order / FOB Price:Get Latest Price

1 Gram

FOB Price: USD 1.0000

  • Min.Order :1 Gram
  • Purity: 99% min
  • Payment Terms : T/T,

Keywords

Recentin 288383-20-0 Cediranib

Quick Details

  • Appearance:White crystallized powder
  • Application:medical intermediate,sex enhancement, muscle shaping
  • PackAge:al foil bag
  • ProductionCapacity:1000|Kilogram|Month
  • Storage: Kept in a well-closed, light-resistant, dry and cool place
  • Transportation: Kept in a well-closed, light-resistant, dry and cool place

Superiority:

1, High quality with competitive price: 
1)Purity≥ 99% 
2)We are manufacturer and can provide high quality products with factory price,offering free samples to test, a few shipping fee only.

 

2.Flexible Payment term
1).we accept every payment term as if you could imagine,such as T/T, Paypal, Money Gram, , Bank transfer.
2).we also offer Bitcoin as a payment to your honor.like Australia,Canada.

 

3, Fast and safe delivery 
1)Parcel can be sent out in 24 hours after payment. Tracking numbers available 
3)Secure and discreet shipment. Various transportation methods for your choice.
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring. 
5)We have special way could ship 0.01kg to sveral kg products a time. We offer melting powder into liquid service. And ship the liquid in special bottles.
6)Offer the latest tracking number for you to check

 

4, We have clients throughout the world. 
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire. 
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility. 
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.

 

5. Good after-sales service.
1)Tell the package update ASAP, and will try best solve when customer encountered various problems.
2)we will teach you recipes and instructions for all kind of steroid to turn powder into liquid, and liquid become sterile ones.

 

Details:

Superiority

Factory Supply Recentin/Cediranib CAS NO.288383-20-0

 

 
Cediranib Basic information
<a drugs"="" style="margin: 0px 10px 0px auto; padding: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 12px; border: 0px; color: rgb(0, 51, 153); outline: none; display: inline-block; overflow: hidden;">Anticancer drugs
Product Name: Cediranib
Synonyms: Cediranib;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Cadiranib (AZD2171);Cediranib(AZD2171);AZD2171;Recentin;Cadiranib;Cediranib R
CAS: 288383-20-0
MF: C25H27FN4O3
MW: 450.51
EINECS:  
Product Categories: APIs;Antineoplastic;Inhibitors
Mol File: 288383-20-0.mol
Cediranib Structure
 
Cediranib Chemical Properties
density 1.285
 
Safety Information
MSDS Information
 
 
Cediranib Usage And Synthesis
Anticancer drugs Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ / Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported. 
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the chemicalbook of Tian Ye.
Usage Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.

 

 

 

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View